Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, San Juan de Alicante, Spain.
PLoS One. 2012;7(9):e44598. doi: 10.1371/journal.pone.0044598. Epub 2012 Sep 13.
BACKGROUND & AIMS: There have been many studies on plasma butyrylcholinesterase in liver dysfunction. However, no data is available about acetylcholinesterase in human cirrhosis, although profound changes have been described in cirrhotic rat models.
Human serum and liver acetylcholinesterase and its molecular forms were determined enzymatically, after butyrylcholinesterase immunodepletion. The distinct species of acetylcholinesterase, with a distinct C-terminus, were determined by western blotting, and the level of liver transcripts by real-time PCR. Liver acetylcholinesterase was also evaluated by immunocytochemistry.
In patients with liver cirrhosis, the activity of plasma acetylcholinesterase (rich in light species), appeared to be apparently unaffected. However, the levels of the soluble readthrough (R) acetylcholinesterase form, an acetylcholinesterase species usually associated with stress and pathology, was increased compared to controls. Human liver acetylcholinesterase activity levels were also unchanged, but protein levels of the acetylcholinesterase-R and other acetylcholinesterase subunit species were increased in the cirrhotic liver. This increase in acetylcholinesterase protein expression in the cirrhotic liver was confirmed by PCR analysis. Immunohistological examination confirmed that acetylcholinesterase immunoreactivity is increased in parenchymal cells of the cirrhotic liver.
We demonstrate significant changes in acetylcholinesterase at the protein and mRNA levels in liver cirrhosis, with no difference in enzymatic activity. The altered expression of acetylcholinesterase protein may reflect changes in its pathophysiological role.
已有许多关于肝功能障碍患者血浆丁酰胆碱酯酶的研究。然而,尽管在肝硬化大鼠模型中描述了深刻的变化,但关于人类肝硬化患者的乙酰胆碱酯酶尚无数据。
用人血清和肝脏乙酰胆碱酯酶及其分子形式进行酶学测定,在丁酰胆碱酯酶免疫耗竭后。通过 Western blot 确定具有独特 C 末端的独特乙酰胆碱酯酶物种,并通过实时 PCR 确定肝转录物的水平。还通过免疫细胞化学评估肝乙酰胆碱酯酶。
在肝硬化患者中,似乎血浆乙酰胆碱酯酶(富含轻物种)的活性未受明显影响。然而,可溶性通读(R)乙酰胆碱酯酶形式的水平与对照相比增加,这是一种通常与应激和病理学相关的乙酰胆碱酯酶物种。人肝乙酰胆碱酯酶活性水平也保持不变,但乙酰胆碱酯酶-R 和其他乙酰胆碱酯酶亚单位物种的蛋白水平在肝硬化肝中增加。PCR 分析证实了肝硬化肝中乙酰胆碱酯酶蛋白表达的增加。免疫组织化学检查证实,乙酰胆碱酯酶免疫反应性在肝硬化肝实质细胞中增加。
我们证明了在肝硬化中乙酰胆碱酯酶在蛋白和 mRNA 水平上发生了显著变化,而酶活性没有差异。乙酰胆碱酯酶蛋白表达的改变可能反映了其病理生理作用的变化。